Sepsis
Conditions
Keywords
sepsis, Heart Failure, AKI
Brief summary
The investigators intend to conduct clinical studies to determine the efficacy of rhBNP in the treatment of septic related dysfunction and kidney dysfunction
Detailed description
Sepsis is one of the common critical diseases in ICU with high mortality. Septic shock patients are often accompanied by multiple organ dysfunction (MODS), of which more than 50% of patients with varying degrees of myocardial injury.The investigators hope to find a drug with a protective effect on cardiac function and kidney function, so as to treat sepsis more effectively in the treatment of sepsis. Recombinant human brain natriuretic peptide (rhBNP) was approved by FDA in 2001 for the treatment of acute decompensated heart failure.These effects play a role in the protection of cardiac and kidney function, and have achieved good results in patients with cardiac insufficiency and AKI caused by cardiac surgery. The investigators are going to carry out related research from the following aspects: 1. To determine the effect of rhBNP on hemodynamics in sepsis based on PiCCO hemodynamic monitoring; 2. To collect and sort out the relevant data to determine the effects of rhBNP on cardiac function and kidney function, including cardiac ultrasound, kidney blood flow index and related laboratory tests. 3. To determine the effect of rhBNP on the final prognosis of patients, including ICU mortality and hospital mortality, ICU time, hospital stay, ventilator use time, kidney replacement therapy time, vasoactive drug dosage and time.
Interventions
1\. To determine the effect of rhBNP on hemodynamics in sepsis based on PiCCO hemodynamic monitoring; 2. To collect and sort out the relevant data to determine the effects of rhBNP on cardiac function and kidney function, including cardiac ultrasound, kidney blood flow index and related laboratory tests. 3. To determine the effect of rhBNP on the final prognosis of patients, including ICU mortality and hospital mortality, ICU time, hospital stay, ventilator use time, kidney replacement therapy time, vasoactive drug dosage and time.
Sponsors
Shanghai Zhongshan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* sepsis complicated with heart failure（Diagnosed by sepsis 3.0） * Heart failure: BNP rises by 600 pg/ml * Age\>=18 years old
Exclusion criteria
* Hemodynamically unstable * Pregnant * Disagree with comprehensive and active life support treatment * coronary heart disease, myocardial infarction, and cardiac insufficiency * chronic renal insufficiency
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the effects of rhBNP(recombinant human brain natriuretic peptide) on cardiac function | 72 hours after rhBNP | The decreasing trend of NTproBNP(N-terminal pro-B-type natriuretic peptide) |
| PiCCO hemodynamic monitoring in recombinant human brain natriuretic peptide group | 72 hours after recombinant human brain natriuretic peptide | The improvement degree of cardiac index in recombinant human brain natriuretic peptide group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ICU mortality and hospital mortality | One month after entering ICU | Comparison between rhBNP group and control group |
| Mechanical ventilation time after entering ICU | 72 hours after recombinant human brain natriuretic peptide | Comparison between rhBNP group and control group |
Countries
China
Contacts
Primary ContactMinjie Ju, PHD
Outcome results
None listed